Compare Amylx Pharmaceuticals Inc (AMLX) vs Anheuser-Busch Inbev SA (BUD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Anheuser-Busch Inbev SA — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Anheuser-Busch Inbev SA trades at $80.02 (market cap $153.32B). The key difference: Anheuser-Busch Inbev SA is far larger — about 77.4× Amylx Pharmaceuticals Inc's market cap, and Anheuser-Busch Inbev SA pays a 1.69% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | BUD | |
|---|---|---|
Market Cap | $1.98B | $153.32B |
Sector | Health | Consumer Staples |
52-Week High | $18.70 | $85.09 |
52-Week Low | $7.64 | $57.10 |
Enterprise Value | $1.70B | $214.50B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
BUD trades at $79.61, up 0.34% on the day, with a bearish technical signal despite recent earnings beats. The company shows stable revenue near $59B and improving net margins, now at 11.9%. Analyst consensus is bullish with a $90.08 price target, supported by dividend payments and strategic investments in premiumization and digital expansion.
Outlook remains positive due to strong fundamentals and analyst support, but risks include industry volume declines and competitive pressures. The stock offers value through dividends and potential upside to target, though technical weakness suggests near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →
